Repeat biopsy for mutational analysis of non-small cell lung cancers resistant to previous chemotherapy: Adequacy and complications

Radiology

Volumn 265, Issue 3, 2012, Pages 939-948

  Yoon, Hyun Jung ^a   Lee, Ho Yun ^a   Lee, Kyung Soo ^a   Choi, Yoon La ^a   Ahn, Myung Ju ^a   Park, Keunchil ^a   Ahn, Jin Seok ^a   Sun, Jong Mu ^a   Kim, Jhingook ^a   Kim, Tae Sung ^a   Chung, Myung Jin ^a   Yi, Chin A ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; BIOPSY TECHNIQUE; CANCER COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONE BEAM COMPUTED TOMOGRAPHY; CONTROLLED STUDY; CORE BIOPSY NEEDLE; DNA EXTRACTION; EMPHYSEMA; EXON; FEMALE; FIBROSING ALVEOLITIS; GENE REARRANGEMENT; HEMATOTHORAX; HEMOPTYSIS; HUMAN; HUMAN TISSUE; LUNG BIOPSY; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PHENOTYPE; PNEUMOTHORAX; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; REPEAT BIOPSY; RISK FACTOR; THORAX RADIOGRAPHY; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; CONE-BEAM COMPUTED TOMOGRAPHY; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; EXONS; FEASIBILITY STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PATIENT SAFETY; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RADIOGRAPHY, INTERVENTIONAL; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETREATMENT;

EID: 84870040449     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.12112613     Document Type: Article

References (43)

1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129-2139. (Pubitemid 38637993)
2. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497-1500. (Pubitemid 38720929)
3. Uramoto H, Mitsudomi T. Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer? Br J Cancer. 2007;96(6):857-863. (Pubitemid 46452294)
4. Uramoto H, Sugio K, Oyama T, et al. Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese. Lung Cancer. 2006;51(1):71-77. (Pubitemid 43088626)
5. Uramoto H, Sugio K, Oyama T, Sugaya M, Hanagiri T, Yasumoto K. Resistance to gefitinib. Int J Clin Oncol. 2006;11(6):487-491. (Pubitemid 44974406)
6. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352(8):786-792. (Pubitemid 40271173)
7. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2(3):e73.
8. Takezawa K, Okamoto I, Tanizaki J, et al. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. Mol Cancer Ther. 2010;9(6):1647-1656.
9. Horn L, Pao W. EML4-ALK: honing in on a new target in non-small-cell lung cancer. J Clin Oncol. 2009;27(26):4232-4235.
10. Mano H. Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. Cancer Sci. 2008;99(12):2349-2355.
11. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561- 566. (Pubitemid 47206930)
12. Choi YL, Soda M, Yamashita Y, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med. 2010;363(18):1734-1739.
13. Fujita S, Mio T, Sonobe M, et al. Accuracy of epidermal growth factor receptor mutation analysis on the basis of small biopsy specimens in patients with nonsmall cell lung cancer. Int J Cancer. 2006;119(7):1751-1752. (Pubitemid 44258791)
14. Hsieh MH, Fang YF, Chang WC, et al. Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer. Lung Cancer. 2006;53(3):311-322.
15. Shih JY, Gow CH, Yu CJ, et al. Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer. 2006;118(4):963-969. (Pubitemid 43157672)
16. Solomon SB, Zakowski MF, Pao W, et al. Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis. AJR Am J Roentgenol. 2010;194(1):266-269.
17. Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 2010;28(2):357-360.
18. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
19. Moore EH. Technical aspects of needle aspiration lung biopsy: a personal perspective. Radiology. 1998;208(2):303-318. (Pubitemid 28373731)
20. Hunninghake GW, Zimmerman MB, Schwartz DA, et al. Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;164(2):193-196. (Pubitemid 34001280)
21. Hwang HS, Chung MJ, Lee JW, Shin SW, Lee KS. C-arm cone-beam CT-guided percutaneous transthoracic lung biopsy: usefulness in evaluation of small pulmonary nodules. AJR Am J Roentgenol. 2010;195(6):W400-W407.
22. Cheung YC, Chang JW, Hsieh JJ, Lin G, Tsai YH. Adequacy and complications of computed tomography-guided core needle biopsy on non-small cell lung cancers for epidermal growth factor receptor mutations demonstration: 18-gauge or 20-gauge biopsy needle. Lung Cancer. 2010;67(2):166-169.
23. Pan Q, Pao W, Ladanyi M. Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas. J Mol Diagn. 2005;7(3):396-403. (Pubitemid 41149655)
24. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004;101(36):13306-13311. (Pubitemid 39209661)
25. Kim H, Yoo SB, Choe JY, et al. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression. J Thorac Oncol. 2011;6(8):1359-1366.
26. Paik JH, Choe G, Kim H, et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol. 2011;6(3):466-472.
27. Eberhard DA, Giaccone G, Johnson BE; Non-Small-Cell Lung Cancer Working Group. Biomarkers of response to epidermal growth factor receptor inhibitors in Non- Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol. 2008;26(6):983-994. (Pubitemid 351398092)
28. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92-98. (Pubitemid 34438899)
29. Min JH, Lee HY, Lim H, et al. Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight. Cancer Chemother Pharmacol. 2011;68(5):1099-1109.
30. Torrisi JM, Schwartz LH, Gollub MJ, Ginsberg MS, Bosl GJ, Hricak H. CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology. 2011;258(1):41-56.
31. Covey AMGR, Gandhi R, Brody LA, Getrajdman G, Thaler HT, Brown KT. Factors associated with pneumothorax and pneumothorax requiring treatment after percutaneous lung biopsy in 443 consecutive patients. J Vasc Interv Radiol. 2004;15(5):479-483. (Pubitemid 38590872)
32. Khan MF, Straub R, Moghaddam SR, et al. Variables affecting the risk of pneumothorax and intrapulmonal hemorrhage in CT-guided transthoracic biopsy. Eur Radiol. 2008;18(7):1356-1363.
33. Yeow KM, Su IH, Pan KT, et al. Risk factors of pneumothorax and bleeding: multivariate analysis of 660 CT-guided coaxial cutting needle lung biopsies. Chest. 2004;126(3):748-754.
34. Tsukada H, Satou T, Iwashima A, Souma T. Diagnostic accuracy of CT-guided automated needle biopsy of lung nodules. AJR Am J Roentgenol. 2000;175(1):239-243. (Pubitemid 30415570)
35. Anderson JM, Murchison J, Patel D. CT-guided lung biopsy: factors influencing diagnostic yield and complication rate. Clin Radiol. 2003;58(10):791-797. (Pubitemid 37236263)
36. Katada K, Kato R, Anno H, et al. Guidance with real-time CT fluoroscopy: early clinical experience. Radiology. 1996;200(3):851-856. (Pubitemid 26282292)
37. Hiraki T, Mimura H, Gobara H, et al. CT fluoroscopy-guided biopsy of 1,000 pulmonary lesions performed with 20-gauge coaxial cutting needles: diagnostic yield and risk factors for diagnostic failure. Chest. 2009;136(6):1612-1617.
38. Kim TJ, Lee JH, Lee CT, et al. Diagnostic accuracy of CT-guided core biopsy of groundglass opacity pulmonary lesions. AJR Am J Roentgenol. 2008;190(1):234-239.
39. Kubota K. From tumor biology to clinical Pet: a review of positron emission tomography (PET) in oncology. Ann Nucl Med. 2001;15(6):471-486. (Pubitemid 34131944)
40. Bar-Shalom R, Yefremov N, Guralnik L, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med. 2003;44(8):1200-1209. (Pubitemid 39655178)
41. Chen CM, Chang JW, Cheung YC, et al. Computed tomography-guided core-needle biopsy specimens demonstrate epidermal growth factor receptor mutations in patients with non-small-cell lung cancer. Acta Radiol. 2008;49(9):991-994.
42. Boldrini L, Gisfredi S, Ursino S, et al. Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis. J Thorac Oncol. 2007;2(12):1086-1090. (Pubitemid 350307900)
43. Pirker R, Herth FJ, Kerr KM, et al. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol. 2010;5(10):1706-1713.